BrainsWay Hosting Key Opinion Leader Webinar on its Deep TMS™ Therapy for Treating Mental Health Disorders

Image

BURLINGTON, MA. and JERUSALEM, August 17, 2021 – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will host a key opinion leader (KOL) webinar on its Deep TMS™ therapy for treating mental health disorders on Tuesday, August 31, 2021, at 11am Eastern Time.

The webinar will feature a presentation by KOL Kimberly Cress, M.D., of Greenbrook TMS NeuroHealth Centers, who will discuss the current treatment landscape and unmet medical need in treating patients with obsessive-compulsive disorder (OCD) and how the BrainsWay Deep TMS therapy fits into the treatment paradigm. Dr. Cress will be available to answer questions following the formal presentations.

BrainsWay’s Chief Medical Officer, Dr. Aron Tendler, will also participate and share some of the robust body of clinical evidence generated to date with Deep TMS. Deep TMS is a noninvasive neurostimulation treatment that produces significant results by directly stimulating deeper and broader areas of the brain. It is a well-tolerated and effective treatment for multiple mental health disorders, including major depressive disorder, OCD, and smoking addiction.

To register for the webinar, please click here.

Dr. Kimberly Cress joined Greenbrook TMS in November 2018 as Regional Medical Director of the Texas region. She also served as President of the Clinical TMS Society (CTMSS) from 2020 to 2021 and is a member of the CTMSS Education and Insurance Committees. Dr. Cress received her medical degree from the University of Texas Health Science Center, San Antonio, and completed her psychiatric residency at the Baylor College of Medicine in Houston. Dr. Cress has treated patients with TMS therapy since April 2010 and completed Harvard Medical School’s Intensive Course in Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, along with completing courses at Duke University in Transcranial Magnetic Stimulation. Dr. Cress says she was drawn to TMS Therapy as a modality because, after finding patients were still struggling with depression and anxiety symptoms despite numerous medication trials and/or therapies, she wanted to help patients regain the quality of life they deserved – without unwanted systemic side effects.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, and the effect of the global COVID-19 health pandemic on our business and continued uncertainty and market impact relating thereto.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s Annual Report on Form 20-F. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov.

Contacts:
BrainsWay:
Scott Areglado
SVP and Chief Financial Officer
617-771-2287
SAreglado@brainsway.com

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com